# ABEONA THERAPEUTICS INC. (ABEO) · Edgar & Edgarette company card

> Abeona Therapeutics (ABEO) grew revenue 66.3% in FY2025 to $6 million, operating margin -1537% against a -3.8% median for pharmaceutical preparations, equity 72.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 318306 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ABEO) · [JSON](https://www.pops4.com/boards/company/ABEO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $6M |
| Revenue growth, 1 year | 66.3% |
| Revenue growth per year | -10.3% |
| Operating margin | -1536.9% (prior year -1346.7%) |
| Net margin | 1223.1% |
| Operating cash flow | −$76M |
| Capital spending | $8M |
| Free cash flow | −$84M |
| Cash | $78M |
| Long-term debt | $20M |
| Total assets | $220M |
| Total equity | $159M |
| Equity ÷ assets | 72.5% |
| Return on equity | 44.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -5.75 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -1536.9% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $5.8M (FY2025), total debt $20.0M. Experience: revenue up 66.3% on the year, down 10.3% a year over 5 years; operating margin -1536.9%, down from -1346.7%. Soundness: equity 72.5% of assets, return on equity 44.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $6.2M and $11.2M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1536.9% against a -3.8% median; growth 66.3% against 13.7%.

Range logged 2026-09-20, receipt 11fbad563de42bd7, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-06-12 ([filing](https://www.sec.gov/Archives/edgar/data/318306/000149315226028369/0001493152-26-028369-index.htm))

## Recent filings

- 8-K · filed 2026-09-15 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/318306/000149315226042702/0001493152-26-042702-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/318306/000149315226037576/0001493152-26-037576-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/0001493152-26-037575-index.htm)
- 8-K · filed 2026-06-12 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/318306/000149315226028458/0001493152-26-028458-index.htm)
- 8-K · filed 2026-06-12 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/318306/000149315226028369/0001493152-26-028369-index.htm)
- 8-K · filed 2026-06-10 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/318306/000149315226028106/0001493152-26-028106-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000318306.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=318306

## Cite

POPS4, Edgar & Edgarette: ABEONA THERAPEUTICS INC. (ABEO) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ABEO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.